Michela Lia

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier et al. · European Journal of Cancer · 2017 · 114 citations

Urology, Eortc 90101, Genitourinary Cancer +9

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Patrick Schöffski, Agnieszka Woźniak, Silvia Stacchiotti et al. · Annals of Oncology · 2017 · 94 citations · Full text

Oncology, Medicine, Metronomic Therapy +11

Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

Olivier Mir, Nathan Touati, Michela Lia et al. · Clinical Cancer Research · 2019 · 85 citations · Full text

Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study

Robin Young, Saskia Litière, Michela Lia et al. · Acta Oncologica · 2017 · 49 citations · Full text

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)

Jean-Pascal Machiels, Paolo Bossi, Jessica Menis et al. · Annals of Oncology · 2018 · 41 citations · Full text